Biography/Memoir

U.S. FDA puts plans to test LSD in anxiety patients in clinical study on hold

The FDA’s move is the latest blow to the psychedelic industry’s attempts to use LSD and other compounds such as psilocybin for therapeutic purposes.

Mind Medicine’s shares fell 10.4% to $1.46 before the bell. In November, shares of Compass Pathways (CMPS.O) fell roughly 16% due to safety concerns on its experimental drug COMP360, which uses the psychedelic active compound in ‘magic’ mushrooms, to treat depression.

Original Article (Reuters):
U.S. FDA puts plans to test LSD in anxiety patients in clinical study on hold
Artwork Fair Use: Benjah-bmm27